Association of Apolipoprotein E Gene Polymorphism with Type 2 Diabetic Nephropathy in the Southern Chinese Population

References

• Satirapoj B. Nephropathy in diabetes. Adv Exp Med Biol. 2012;771:107–122. doi:10.1007/978-1-4614-5441-0_11
   PubMed Web of Science ®Google Scholar
• Jadawji C, Crasto W, Gillies C, et al. Prevalence and progression of diabetic nephropathy in South Asian, white European and African Caribbean people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21(3):658–673. doi:10.1111/dom.13569
   PubMed Web of Science ®Google Scholar
• Demir Y, Ceylan H, Turkes C, Beydemir S. Molecular docking and inhibition studies of vulpinic, carnosic and usnic acids on polyol pathway enzymes. J Biomol Struct Dyn. 2022;40(22):12008–12021. doi:10.1080/07391102.2021.1967195
   PubMed Web of Science ®Google Scholar
• Sever B, Altintop MD, Demir Y, Akalin Ciftci G, Beydemir S, Ozdemir A. Design, synthesis, in vitro and in silico investigation of aldose reductase inhibitory effects of new thiazole-based compounds. Bioorg Chem. 2020;102:104110. doi:10.1016/j.bioorg.2020.104110
   PubMed Web of Science ®Google Scholar
• Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28(1):164–176. doi:10.2337/diacare.28.1.164
   PubMed Web of Science ®Google Scholar
• McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BM. Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30(1):127–135. doi:10.1681/ASN.2018050531
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014;37(10):2864–2883. doi:10.2337/dc14-1296
   PubMed Web of Science ®Google Scholar
• Li Y, Ning Y, Shen B, et al. Temporal trends in prevalence and mortality for chronic kidney disease in China from 1990 to 2019: an analysis of the Global Burden of Disease Study 2019. Clin Kidney J. 2023;16(2):312–321. doi:10.1093/ckj/sfac218
   PubMed Web of Science ®Google Scholar
• Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S79–83. doi:10.2337/diacare.27.2007.s79
   PubMedGoogle Scholar
• Sever B, Altıntop MD, Demir Y, et al. An extensive research on aldose reductase inhibitory effects of new 4H-1,2,4-triazole derivatives. J Mol Struct. 2021;1224:129446. doi:10.1016/j.molstruc.2020.129446
   Web of Science ®Google Scholar
• Sever B, Altintop MD, Demir Y, et al. Identification of a new class of potent aldose reductase inhibitors: design, microwave-assisted synthesis, in vitro and in silico evaluation of 2-pyrazolines. Chem Biol Interact. 2021;345:109576. doi:10.1016/j.cbi.2021.109576
   PubMed Web of Science ®Google Scholar
• Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy--a review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445–1454.
   PubMed Web of Science ®Google Scholar
• Akdağ M, Özçelik AB, Demir Y, Beydemir Ş. Design, synthesis, and aldose reductase inhibitory effect of some novel carboxylic acid derivatives bearing 2-substituted-6-aryloxo-pyridazinone moiety. J Mol Struct. 2022;1258:132675. doi:10.1016/j.molstruc.2022.132675
   Web of Science ®Google Scholar
• Turkes C, Arslan M, Demir Y, Cocaj L, Nixha AR, Beydemir S. N-substituted phthalazine sulfonamide derivatives as non-classical aldose reductase inhibitors. J Mol Recognit. 2022;35(12):e2991. doi:10.1002/jmr.2991
   PubMed Web of Science ®Google Scholar
• Cheung CY, Ma MKM, Chak WL, Tang SCW. Cancer risk in patients with diabetic nephropathy: a retrospective cohort study in Hong Kong. Medicine. 2017;96(38):e8077. doi:10.1097/MD.0000000000008077
   PubMed Web of Science ®Google Scholar
• Mise K, Galvan DL, Danesh FR. Shaping up mitochondria in diabetic nephropathy. Kidney360. 2020;1(9):982–992. doi:10.34067/kid.0002352020
   PubMedGoogle Scholar
• Seyed Ahmadi S, Svensson AM, Pivodic A, Rosengren A, Lind M. Risk of atrial fibrillation in persons with type 2 diabetes and the excess risk in relation to glycaemic control and renal function: a Swedish cohort study. Cardiovasc Diabetol. 2020;19(1):9. doi:10.1186/s12933-019-0983-1
   PubMed Web of Science ®Google Scholar
• Alim Z, Kilic D, Demir Y. Some indazoles reduced the activity of human serum paraoxonase 1, an antioxidant enzyme: in vitro inhibition and molecular modeling studies. Arch Physiol Biochem. 2019;125(5):387–395. doi:10.1080/13813455.2018.1470646
   PubMed Web of Science ®Google Scholar
• Caliskan B, Demir Y, Turkes C. Ophthalmic drugs: in vitro paraoxonase 1 inhibition and molecular docking studies. Biotechnol Appl Biochem. 2022;69(6):2273–2283. doi:10.1002/bab.2284
   PubMed Web of Science ®Google Scholar
• Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 2014;63(12):1469–1479. doi:10.1016/j.metabol.2014.08.010
   PubMed Web of Science ®Google Scholar
• Ng MC, Baum L, So WY, et al. Association of lipoprotein lipase S447X, apolipoprotein E exon 4, and apoC3 −455T>C polymorphisms on the susceptibility to diabetic nephropathy. Clin Genet. 2006;70(1):20–28. doi:10.1111/j.1399-0004.2006.00628.x
   PubMed Web of Science ®Google Scholar
• Shah VN, Cheema BS, Sharma R, et al. ACACbeta gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes. Mol Cell Biochem. 2013;372(1–2):191–198. doi:10.1007/s11010-012-1460-2
   PubMed Web of Science ®Google Scholar
• Wu LS, Hsieh CH, Pei D, Hung YJ, Kuo SW, Lin E. Association and interaction analyses of genetic variants in ADIPOQ, ENPP1, GHSR, PPARgamma and TCF7L2 genes for diabetic nephropathy in a Taiwanese population with type 2 diabetes. Nephrol Dial Transplant. 2009;24(11):3360–3366. doi:10.1093/ndt/gfp271
   PubMed Web of Science ®Google Scholar
• Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res. 2014;55(3):561–572. doi:10.1194/jlr.P040501
   PubMed Web of Science ®Google Scholar
• Demir Y, Tokali FS, Kalay E, et al. Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors. Mol Divers. 2023;27(4):1713–1733. doi:10.1007/s11030-022-10526-1
   PubMed Web of Science ®Google Scholar
• Tokali FS, Demir Y, Turkes C, Dincer B, Beydemir S. Novel acetic acid derivatives containing quinazolin-4(3H)-one ring: synthesis, in vitro, and in silico evaluation of potent aldose reductase inhibitors. Drug Dev Res. 2023;84(2):275–295. doi:10.1002/ddr.22031
   PubMed Web of Science ®Google Scholar
• Beydemir S, Demir Y. Antiepileptic drugs: impacts on human serum paraoxonase-1. J Biochem Mol Toxicol. 2017;31(6). doi:10.1002/jbt.21889
   Web of Science ®Google Scholar
• DemİR Y, BeydemİR Ş. Purification, refolding, and characterization of recombinant human paraoxonase-1. Turk J Chem. 2015;39:764–776. doi:10.3906/kim-1501-51
   Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622–630. doi:10.1126/science.3283935
   PubMed Web of Science ®Google Scholar
• Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–537. doi:10.1146/annurev.genom.1.1.507
   PubMed Web of Science ®Google Scholar
• Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology. 2019;51(2):165–176. doi:10.1016/j.pathol.2018.11.002
   PubMed Web of Science ®Google Scholar
• Saadat M. Apolipoprotein E (APOE) polymorphisms and susceptibility to breast cancer: a Meta-Analysis. Cancer Res Treat. 2012;44(2):121–126. doi:10.4143/crt.2012.44.2.121
   PubMed Web of Science ®Google Scholar
• Horejsi B, Ceska R. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiol Res. 2000;49(Suppl 1):S63–9.
   PubMedGoogle Scholar
• Achouri-Rassas A, Ali NB, Cherif A, et al. Association between ACE polymorphism, cognitive phenotype and APOE E4 allele in a Tunisian population with Alzheimer disease. J Neural Transm. 2016;123(3):317–321. doi:10.1007/s00702-015-1468-3
   PubMed Web of Science ®Google Scholar
• Al-Dabbagh NM, Al-Dohayan N, Arfin M, Tariq M. Apolipoprotein E polymorphisms and primary glaucoma in Saudis. Mol Vis. 2009;15:912–919.
   PubMed Web of Science ®Google Scholar
• Jairani PS, Aswathy PM, Gopala S, Verghese J, Mathuranath PS. Interaction with the MAPT H1H1 genotype increases dementia risk in APOE epsilon4 carriers in a population of southern India. Dement Geriatr Cogn Disord. 2016;42(5–6):255–264. doi:10.1159/000447446
   PubMed Web of Science ®Google Scholar
• Zhong Z, Wu H, Wu H, Zhao P. Analysis of apolipoprotein E genetic polymorphism in a large ethnic Hakka population in southern China. Genet Mol Biol. 2018;41(4):742–749. doi:10.1590/1678-4685-GMB-2017-0301
   PubMed Web of Science ®Google Scholar
• Jiang Y, Ma L, Han C, et al. Effects of Apolipoprotein E isoforms in diabetic nephropathy of Chinese Type 2 Diabetic Patients. J Diabetes Res. 2017;2017:3560920. doi:10.1155/2017/3560920
   PubMed Web of Science ®Google Scholar
• Araki S, Koya D, Makiishi T, et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: results of a prospective observational follow-up study. Diabetes Care. 2003;26(8):2416–2420. doi:10.2337/diacare.26.8.2416
   PubMed Web of Science ®Google Scholar
• Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531–537. doi:10.2337/diacare.29.03.06.dc05-1254
   PubMed Web of Science ®Google Scholar
• Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J Nephrol. 2002;15(4):368–373.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346(15):1145–1151. doi:10.1056/NEJMcp011773
   PubMed Web of Science ®Google Scholar
• American Diabetes A. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36(Suppl 1):S11–66. doi:10.2337/dc13-S011
   PubMedGoogle Scholar
• Turkes C, Demir Y, Beydemir S. Anti-diabetic properties of calcium channel blockers: inhibition effects on aldose reductase enzyme activity. Appl Biochem Biotechnol. 2019;189(1):318–329. doi:10.1007/s12010-019-03009-x
   PubMed Web of Science ®Google Scholar
• Xu M, Wu P, Shen F, Ji J, Rakesh KP. Chalcone derivatives and their antibacterial activities: current development. Bioorg Chem. 2019;91:103133. doi:10.1016/j.bioorg.2019.103133
   PubMed Web of Science ®Google Scholar
• Gan C, Zhang Y, Liang F, Guo X, Zhong Z. Effects of APOE gene epsilon4 allele on serum lipid profiles and risk of cardiovascular disease and tumorigenesis in southern Chinese population. World J Surg Oncol. 2022;20(1):280. doi:10.1186/s12957-022-02748-2
   PubMed Web of Science ®Google Scholar
• Hou J, Deng Q, Guo X, Deng X, Zhong W, Zhong Z. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Hakka postmenopausal women in southern China. Lipids Health Dis. 2020;19(1):139. doi:10.1186/s12944-020-01323-6
   PubMed Web of Science ®Google Scholar
• Altintop MD, Demir Y, Turkes C, et al. A new series of hydrazones as small-molecule aldose reductase inhibitors. Arch Pharm. 2023;356(4):e2200570. doi:10.1002/ardp.202200570
   PubMed Web of Science ®Google Scholar
• Ertano BY, Demir Y, Nural Y, Erdoğan O. Investigation of the effect of acylthiourea derivatives on diabetes-associated enzymes. ChemistrySelect. 2022;7(46):e202204149. doi:10.1002/slct.202204149
   Web of Science ®Google Scholar
• Khalil YA, Rabes JP, Boileau C, Varret M. APOE gene variants in primary dyslipidemia. Atherosclerosis. 2021;328:11–22. doi:10.1016/j.atherosclerosis.2021.05.007
   PubMed Web of Science ®Google Scholar
• Yin YW, Qiao L, Sun QQ, et al. Influence of apolipoprotein E gene polymorphism on development of type 2 diabetes mellitus in Chinese Han population: a meta-analysis of 29 studies. Metabolism. 2014;63(4):532–541. doi:10.1016/j.metabol.2013.12.008
   PubMed Web of Science ®Google Scholar
• Reis KA, Ebinc FA, Koc E, et al. Association of the angiotensinogen M235T and APO E gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. Ren Fail. 2011;33(5):469–474. doi:10.3109/0886022X.2011.568133
   PubMed Web of Science ®Google Scholar
• Atta MI, Abo Gabal K, El-Hadidi K, Swellam M, Genina A, Zaher NF. Apolipoprotein E genotyping in Egyptian diabetic nephropathy patients. IUBMB Life. 2016;68(1):58–64. doi:10.1002/iub.1460
   PubMed Web of Science ®Google Scholar
• Rall SC Jr, Weisgraber KH, Mahley RW. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982;257(8):4171–4178. doi:10.1016/S0021-9258(18)34702-1
   PubMed Web of Science ®Google Scholar
• Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci U S A. 1983;80(1):283–287. doi:10.1073/pnas.80.1.283
   PubMed Web of Science ®Google Scholar
• Seripa D, D’Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011;14(5):491–500. doi:10.1089/rej.2011.1169
   PubMed Web of Science ®Google Scholar
• Rao H, Wu H, Yu Z, Huang Q. APOE genetic polymorphism rs7412 T/T genotype may be a risk factor for essential hypertension among Hakka people in Southern China. Int J Hypertens. 2022;2022:8145896. doi:10.1155/2022/8145896
   PubMed Web of Science ®Google Scholar
• Karahan Z, Ugurlu M, Ucaman B, et al. Relation between apolipoprotein E gene polymorphism and severity of coronary artery disease in acute myocardial infarction. Cardiol Res Pract. 2015;2015:363458. doi:10.1155/2015/363458
   PubMed Web of Science ®Google Scholar
• Demirag MD, Onen HI, Karaoguz MY, et al. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52(12):3399–3403. doi:10.1007/s10620-007-9740-5
   PubMed Web of Science ®Google Scholar
• Chaudhary R, Likidlilid A, Peerapatdit T, et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36. doi:10.1186/1475-2840-11-36
   PubMed Web of Science ®Google Scholar
• Broce IJ, Tan CH, Fan CC, et al. Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease. Acta Neuropathol. 2019;137(2):209–226. doi:10.1007/s00401-018-1928-6
   PubMed Web of Science ®Google Scholar
• Eto M, Saito M, Okada M, et al. Apolipoprotein E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis. 2002;40(2):243–251. doi:10.1053/ajkd.2002.34502
   PubMed Web of Science ®Google Scholar
• Ilhan N, Kahraman N, Seckin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct. 2007;25(5):527–532. doi:10.1002/cbf.1348
   PubMed Web of Science ®Google Scholar
• Karimoei M, Pasalar P, Mehrabzadeh M, et al. Association between apolipoprotein E polymorphism and nephropathy in Iranian diabetic patients. Saudi J Kidney Dis Transpl. 2017;28(5):997–1002. doi:10.4103/1319-2442.215137
   PubMedGoogle Scholar
• Erdogan M, Eroglu Z, Biray C, et al. The relationship of the apolipoprotein E gene polymorphism Turkish Type 2 diabetic patients with and without nephropathy. J Endocrinol Invest. 2009;32(3):219–222. doi:10.1007/BF03346455
   PubMed Web of Science ®Google Scholar
• Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab. 2000;26(4):254–264.
   PubMed Web of Science ®Google Scholar
• Kasiske BL, O’Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int. 1990;37(3):880–891. doi:10.1038/ki.1990.62
   PubMed Web of Science ®Google Scholar
• Hung CC, Tsai JC, Kuo HT, Chang JM, Hwang SJ, Chen HC. Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud. 2013;10(2–3):110–120. doi:10.1900/RDS.2013.10.110
   PubMedGoogle Scholar
• Grone HJ, Hohbach J, Grone EF. Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl. 1996;54:S18–22.
   PubMedGoogle Scholar
• Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56(5):1627–1637. doi:10.1046/j.1523-1755.1999.00721.x
   PubMed Web of Science ®Google Scholar
• Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ, Lai YH. Role of lipid control in diabetic nephropathy. Kidney Int Suppl. 2005;94:S60–2. doi:10.1111/j.1523-1755.2005.09415.x
   Google Scholar
• Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999;71:S22–4. doi:10.1046/j.1523-1755.1999.07106.x
   Google Scholar